APA (7th ed.) Citation

L, R., JW, L., SK, L., AB, B., Jr, F. G., PL, K., . . . PJ, O. (2022). A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161. Investigational new drugs, 40(6), 1306. https://doi.org/10.1007/s10637-022-01311-w

Chicago Style (17th ed.) Citation

L, Rajdev, Lee JW, Libutti SK, Benson AB, Fisher GA Jr, Kunz PL, Hendifar AE, Catalano P, and O'Dwyer PJ. "A Phase II Study of Sapanisertib (TAK-228) a MTORC1/2 Inhibitor in Rapalog-resistant Advanced Pancreatic Neuroendocrine Tumors (PNET): ECOG-ACRIN EA2161." Investigational New Drugs 40, no. 6 (2022): 1306. https://doi.org/10.1007/s10637-022-01311-w.

MLA (9th ed.) Citation

L, Rajdev, et al. "A Phase II Study of Sapanisertib (TAK-228) a MTORC1/2 Inhibitor in Rapalog-resistant Advanced Pancreatic Neuroendocrine Tumors (PNET): ECOG-ACRIN EA2161." Investigational New Drugs, vol. 40, no. 6, 2022, p. 1306, https://doi.org/10.1007/s10637-022-01311-w.